Zenas BioPharma (ZBIO) Competitors $15.41 -0.30 (-1.91%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ZBIO vs. LGND, FOLD, BCRX, CLDX, DVAX, MNKD, INVA, NVAX, OPK, and GERNShould you be buying Zenas BioPharma stock or one of its competitors? The main competitors of Zenas BioPharma include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Zenas BioPharma vs. Its Competitors Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies MannKind Innoviva Novavax OPKO Health Geron Ligand Pharmaceuticals (NASDAQ:LGND) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Do insiders and institutionals hold more shares of LGND or ZBIO? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 16.5% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable valuation & earnings, LGND or ZBIO? Ligand Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$181.49M14.11-$4.03M-$7.12-18.64Zenas BioPharma$5M128.92-$156.99M-$3.55-4.34 Is LGND or ZBIO more profitable? Zenas BioPharma has a net margin of 0.00% compared to Ligand Pharmaceuticals' net margin of -73.07%. Zenas BioPharma's return on equity of 0.00% beat Ligand Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals-73.07% -7.83% -6.92% Zenas BioPharma N/A N/A N/A Do analysts rate LGND or ZBIO? Ligand Pharmaceuticals currently has a consensus target price of $150.00, suggesting a potential upside of 13.02%. Zenas BioPharma has a consensus target price of $36.67, suggesting a potential upside of 137.94%. Given Zenas BioPharma's higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Zenas BioPharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor LGND or ZBIO? In the previous week, Ligand Pharmaceuticals had 6 more articles in the media than Zenas BioPharma. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 3 mentions for Zenas BioPharma. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat Zenas BioPharma's score of 1.17 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryZenas BioPharma beats Ligand Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Zenas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBIO vs. The Competition Export to ExcelMetricZenas BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$657.22M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-4.3417.6228.7823.81Price / Sales128.92179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book2.068.508.275.54Net Income-$156.99M-$55.06M$3.25B$259.28M7 Day Performance-1.60%-3.99%-3.70%-4.64%1 Month Performance50.78%9.58%4.34%4.41%1 Year PerformanceN/A6.70%25.90%17.95% Zenas BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBIOZenas BioPharma1.659 of 5 stars$15.41-1.9%$36.67+137.9%N/A$657.22M$5M-4.34N/APositive NewsLGNDLigand Pharmaceuticals4.1941 of 5 stars$131.58-2.5%$147.17+11.8%+27.2%$2.54B$167.13M-18.4880Positive NewsUpcoming EarningsAnalyst ForecastFOLDAmicus Therapeutics4.0015 of 5 stars$6.13+0.2%$16.22+164.6%-38.0%$1.89B$528.29M-68.10480Trending NewsAnalyst UpgradeBCRXBioCryst Pharmaceuticals4.2262 of 5 stars$8.09-2.1%$16.70+106.4%+11.8%$1.69B$450.71M-31.12530News CoverageUpcoming EarningsCLDXCelldex Therapeutics1.2681 of 5 stars$21.95-0.3%$50.11+128.3%-40.9%$1.46B$7.56M-8.13150News CoveragePositive NewsUpcoming EarningsDVAXDynavax Technologies4.1979 of 5 stars$11.19-0.9%$24.00+114.5%-0.5%$1.34B$277.25M-21.52350Upcoming EarningsMNKDMannKind3.3004 of 5 stars$3.82-3.5%$9.86+158.0%-32.4%$1.16B$285.50M38.20400News CoverageUpcoming EarningsAnalyst DowngradeINVAInnoviva4.1878 of 5 stars$18.46-0.4%$40.33+118.5%-3.4%$1.16B$369.84M-18.28100Positive NewsGap UpNVAXNovavax4.5812 of 5 stars$7.01-3.7%$15.86+126.2%-47.8%$1.14B$682.16M2.651,990News CoverageUpcoming EarningsGap DownOPKOPKO Health4.0412 of 5 stars$1.35flat$2.75+103.7%-13.5%$1.07B$713.10M-19.282,997News CoverageEarnings ReportGap DownGERNGeron3.0449 of 5 stars$1.14-1.3%$4.61+306.3%-75.5%$722.90M$76.99M-5.40229Upcoming Earnings Related Companies and Tools Related Companies LGND Alternatives FOLD Alternatives BCRX Alternatives CLDX Alternatives DVAX Alternatives MNKD Alternatives INVA Alternatives NVAX Alternatives OPK Alternatives GERN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZBIO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
